Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CREBBP | Q92793 | 9/20 | 0.43 |
| ▸ | BRD4 | O60885 | 8/20 | 0.43 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17075088 | 0.88 | ALDH1A1 (0.49) | ALDH1A1CREBBPBRD4EP300TSHR | |
| SCHEMBL17075148 | 0.84 | ALDH1A1 (0.48) | ALDH1A1CREBBPBRD4EP300TSHR | |
| SCHEMBL30797137 | 0.77 | ALDH1A1 (0.43) | ALDH1A1CREBBPBRD4EP300TSHR | |
| SCHEMBL6644277 | 0.75 | IDO1 (0.44) | ALDH1A1CREBBPNPC1 | |
| SCHEMBL17075145 | 0.74 | ALDH1A1 (0.50) | ALDH1A1CREBBPBRD4EP300TSHR | |
| SCHEMBL8693351 | 0.74 | ALDH1A1 (0.62) | ALDH1A1CREBBPBRD4EP300TSHR | |
| SCHEMBL25111957 | 0.70 | ALDH1A1 (0.57) | ALDH1A1CREBBPBRD4EP300TSHR | |
| SCHEMBL9366324 | 0.70 | CREBBP (0.58) | ALDH1A1CREBBPBRD4EP300TSHR | |
| SCHEMBL30528072 | 0.70 | ALDH1A1 (0.57) | ALDH1A1CREBBPBRD4EP300TSHR | |
| SCHEMBL434921 | 0.70 | CREBBP (0.58) | ALDH1A1CREBBPBRD4EP300TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3116873-B1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL | ABBVIE DEUTSCHLAND (DE) | 2018-02-28 | — | — | EP | disclosed |
| US-20170158693-A1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL | ABBVIE DEUTSCHLAND (DE) | 2017-06-08 | — | — | US | disclosed |
| US-9573950-B2 | Substituted [1,4]diazepino[6,7,1-ij]quinolines as serotonin 5-HT2C receptor modulators | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2017-02-21 | — | — | US | disclosed |
| EP-3116873-A1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-01-18 | — | — | EP | disclosed |
| US-20150259343-A1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-09-17 | — | — | US | disclosed |
| WO-2015136090-A1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158693-A1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL | HTR2C, HTR2A, HTR5A | ALDH1A1 949/4885CREBBP 2507/4885BRD4 1775/4885 |
| US-20150259343-A1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL | HTR2C, HTR2A, HTR5A | ALDH1A1 949/4885CREBBP 2507/4885BRD4 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.